Log in to our secure, personalized website to manage your care (formerly myMDAnderson).
If you are ready to make an appointment, select a button on the right. If you have questions about MD Anderson’s appointment process, our information page may be the best place to start.
Appointment Information
"We choose to go to the moon in this decade and do the other things, not because they are easy but because they are hard."
John F. Kennedy
Inspired by America’s drive 60 years ago to put a man on the moon, MD Anderson has an ambitious and comprehensive action plan to make a giant leap for patients.
Scroll Ahead
We’re tackling cancer with a new plan — one that aims to improve cancer prevention, early detection and treatment. Our platforms, the research engines fueling the projects, are supporting us along the way. And innovation, collaboration and scale get us there faster. They give us the framework we need for success, and speed up development for new and more effective care. It’s bold. But boldness brings progress.
We've changed the game with our fresh approach to organizing our resources to end cancer. Through this novel organizational paradigm, we are going beyond discovery, leading to new drugs, new ways to prevent cancer and new ways of sharing knowledge.
We have more than 21,000 employees focused on one mission: to end cancer. Each year we treat more than 100,000 people, and we have more than 1,200 clinical trials open that yield significant results and extend our ability to execute. With our critical mass and global reach, we are poised to make an enormous impact on the lives of cancer patients and their families.
We believe in the power of collective, interdisciplinary thinking. That’s why we’ve pooled our resources to attack cancer as a unified force. This team-science mentality accelerates research efforts by taking a more agile approach to leveraging the right resources and infrastructure. Our strategic business alliances, Cancer Network and Sister Institution Network help us make a global impact.
Launch of Moon Shots Program
September 2012
Algorithm raises ovarian tumor removal success rates to 80%
October 2014
Moon Shots Program expands to include six additional cancer types
October 2015
Moon Shots experts join Parker Institute for Cancer Immunotherapy
April 2016
Early treatment biopsies predict response to melanoma immunotherapy
August 2016
First IACS-developed drug to starve cancer cells enters clinical trial
October 2016
MD Anderson designated first Project ECHO superhub for oncology
February 2017
Targeted therapy poziotinib effective in certain lung cancers
October 2017
Gut microbiome found to impact melanoma response to immunotherapy
November 2017
Engineered cold virus shows promise in treating glioblastoma
February 2018
Immunologist Jim Allison awarded Nobel Prize
October 2018
Texas raises tobacco sale age to 21
May 2019
Novel targeted therapy combo effective in frontline CLL treatment
May 2019
CD19 CAR NK cells achieve high responses in hematologic cancers
February 2020
The lessons we learn along the way will help strengthen the Moon Shots Program®. As we work to end these cancers, we’ll better understand how to end all cancer. And then we’ll do it.
The best plans start with a focus. That’s why MD Anderson's Moon Shots Program is centered around specific types of cancer. Some of them are related to each other, which can speed up research, while others affect many patients. But the lessons we learn from our progress with each of these types will help teach us how to best tackle all cancers.
Lymphoma is the most common form of hematological malignancy, or blood cancer, in the developed world. The two main types of lymphoma are Hodgkin Lymphoma and non-Hodgkin Lymphoma. About 85% of non-Hodgkin Lymphomas form from B cells, which are an important part of the body’s immune system.
Learn more about how MD Anderson’s experts are treating non-Hodgkin Lymphomas.
B-CELL LYMPHOMA MOON SHOT
Colonoscopy technology has made early detection and treatment possible and has saved many lives. But this screening test is invasive, unpleasant and expensive and does not always find the less common types of colon cancer. Through the Colorectal Cancer Moon Shot®, MD Anderson scientists are focused on developing a blood test that will spot the earliest signs of the disease. So far they have identified two promising markers in the bloodstream that warn about precancerous changes in the colon. They are working to identify others.
Colorectal Cancer Moon Shot
Current treatments for glioblastoma and other brain and central nervous system tumors are low in number and short on effectiveness. The Glioblastoma Moon Shot® aims to quadruple the five-year survival rate through investigation of existing and experimental immunotherapeutic drugs and customized immune cells designed to attack specific targets within tumors. Other projects include further clinical development of an engineered, cancer-killing virus invented at MD Anderson, identification of new targeted therapies and exploration of how such advances could be combined with immunotherapy.
GLIOBLASTOMA MOON SHOT
HPV is a group of more than 150 related viruses. The lifetime risk of acquiring an HPV infection is 75–80%. While certain forms of the virus cause common skin warts (papillomas), others can lead to cancer. Each year hundreds of thousands of men and women around the globe are diagnosed with HPV-related cancers, and in many areas more than half of those patients will die.
HPV-Related Cancers Moon ShotCLL develops slowly, creating defective white blood cells that can’t produce antibodies against infection. The average age of patients at diagnosis is 72. As more people age, more will develop CLL.
We’re leading the attack against CLL by using new, targeted therapies to combat relapsed or resistant disease. We’re launching innovative combination clinical trials and applying immunotherapy to find and kill cells that survive initial treatment.
LEUKEMIA - CLL MOON SHOT
MDS and AML are among the most tragic leukemias in terms of prognosis. There’s no cure for MDS, and AML has a cure rate of less than 30%. But MD Anderson physicians and scientists give patients hope.
LEUKEMIA - MDS & AML MOON SHOTThe Lung Cancer Moon Shot® is developing new integrated approaches to change the way we prevent, detect and treat lung cancer. The lung cancer prevention project is focused on developing new approaches to prevent youth smoking and to enhance adult smoking cessation strategies through novel, personalized clinical trials. The early detection project is working to identify predictive blood-based biomarkers to detect lung cancer at an early stage when it is most curable. The GEMINI project is aimed at changing the paradigm for treating lung cancer by performing molecular profiling on lung cancer patients and then using the information to personalize treatments and develop new targeted / immunotherapy regimens.
LUNG CANCER MOON SHOT
MD Anderson is home to one of the largest melanoma and skin cancer clinics in the world. This has led to a nearly unrivaled level of expertise. Learn more about how MD Anderson’s Melanoma Moon Shot® is Making Cancer History®.
MELANOMA MOON SHOT
Multiple myeloma is the second most common blood cancer, with 27,000 new diagnoses in the U.S. annually. Prevalence is steadily increasing. The disease is caused by rogue plasma cells that accumulate in the bone marrow and interfere with the normal production of other blood cells. Symptoms include bone lesions, anemia and kidney failure.
MD Anderson’s High-Risk Multiple Myeloma Moon Shot® is consolidating resources across MD Anderson and aiming to delay and ultimately prevent progression of the disease, especially for high-risk patients who have had few answers until now.
MULTIPLE MYELOMA MOON SHOT
High-grade serous ovarian cancer (HGSOC) is an aggressive subtype which causes nearly 90% of ovarian cancer deaths.
MD Anderson works every day to advance leading-edge care and research aimed at saving more lives.
OVARIAN MOON SHOTFrom ultrasensitive detection technologies to catch this cancer early, to new treatment, including immunotherapy, the efforts of the Pancreatic Cancer Moon Shot® bring hope for those diagnosed with this deadly type of cancer.
Pancreatic cancer is the most deadly cancer, taking the majority of lives it impacts. The five-year survival rate is a dismal 5%, and advances remain stagnated. But there is hope. MD Anderson leaders in pancreatic cancer have designed a framework for the exciting Pancreatic Cancer Moon Shot that they expect will significantly improve survival within the next 10 years.
PANCREATIC CANCER MOON SHOTResearchers at MD Anderson are working hard to develop a deeper understanding of the biology of prostate cancer and a new array of therapies that can control the disease and preserve patients’ quality of life.
PROSTATE MOON SHOTThe research engines of the Moon Shots Program® allow us to rapidly translate findings into effective treatment and prevention approaches. Providing scientific expertise and specialized infrastructure to support the program, the platforms are deeply involved in flagship projects for Moon Shot initiatives, advancing the latest clinical trials on new drugs, immunotherapies and combination treatments to achieve vastly improved patient care and save lives.
We use platforms to generate and analyze data at the molecular level to better understand, detect and treat cancer. Because sometimes the biggest changes start small.
Our frameworks structure and aggregate patient data to increase research productivity and to improve patient care and research. This frees up researchers to focus on new theories for accelerated progress.
This research engine informs and educates. We can use community-based efforts to influence people to screen, detect early and avoid certain behaviors to prevent cancer before it even starts.
We have entities dedicated to developing new drugs to help cure cancer faster — and more safely, too. Our aim is to translate discoveries into usable drugs (and cures) quickly and effectively.
We run a lot of clinical trials. Which means more progress, and more success. MD Anderson has more than 165 immunotherapy clinical trials underway that have enrolled 3,500 patients. And we’re just getting started.
Learn More
The University of Texas MD Anderson Cancer Center and Xilis today announced a strategic collaboration to deploy Xilis’ proprietary MicroOrganoSphere...
The University of Texas MD Anderson Cancer Center and Federation Bio today announced a strategic collaboration to design and manufacture a...
